A study to investigate mocertatug rezetecan compared with SoC in participants with PROC
Research type
Research Study
Full title
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with standard of care in participants with platinum-resistant ovarian cancer (BEHOLD-Ovarian01)
IRAS ID
1013405
Contact name
Faatimah Arshad
Contact email
Sponsor organisation
GlaxoSmithKline Research & Development Limited
ISRCTN Number
--
Clinicaltrials.gov Identifier
Research summary
This is an open-label study, which means both the researchers and participants will know which treatment is being given. Participants will be randomly assigned to one of two groups. This is called randomisation. The two treatment groups are:
• Group 1: Participants will receive the study medicine, Mo-Rez.
• Group 2: Participants will receive the standard of care, chosen by the study doctor from a list of approved medicines.
Participants will be closely monitored for safety throughout the study and will continue treatment until their disease gets worse or they experience any side effects.
Participants will receive either Mo-Rez or standard of care treatment such as paclitaxel, pembrolizumab and paclitaxel with or without bevacizumab, pegylated liposomal doxorubicin (PLD), topotecan, or gemcitabine. Treatments will be given as an infusion into a vein (intravenously).
The main objective of the study is to evaluate how well the study medicine, Mo-Rez, works compared with standard of care in treating participants with PROC. Main Inclusion criteria: Women participants will be included in the study if they:
• Are at least 18 years old.
• Have a confirmed diagnosis of ovarian, peritoneal, or fallopian tube cancer that has returned and is now resistant to standard platinum-based chemotherapy.
• Have received between one and four previous courses of treatment for their cancer.
Main Exclusion criteria: Women participants will be excluded from the study if they:
• Have ovarian cancer that did not respond to the first platinum-based treatment or got worse within 3 months after the last dose of that treatment.
• Have any other types of cancer, apart from ovarian cancer, that got worse or required treatment within the past 3 years, except for certain skin cancers or early-stage cancers.
• Have ever had a bone marrow or solid organ transplant.
This study will be conducted in agreement with the protocol and will follow international ethical guidelines.REC name
Wales REC 1
REC reference
26/WA/0091
Date of REC Opinion
3 Aug 2026
REC opinion
Further Information Favourable Opinion